Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lithium Carbonate→

Lithium Carbonate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
554-13-2
Molecular formula
CLi2O3
Molecular weight
73.9 g/mol
Drug class
Mood stabiliserlithium salt used in bipolar disorder
Mechanism of action
The mechanism of mood stabilisation is not fully understood. Lithium modulates intracellular signalling pathways, including inhibition of glycogen synthase kinase-3 and effects on inositol-phosphate metabolism, and influences neuronal second-messenger systems.
Indications / reported uses
  • Treatment of acute manic episodes and maintenance treatment of bipolar I disorder in adults, with serum lithium concentration, renal, thyroid and electrolyte monitoring; indication and age criteria depend on the product label

Sources: US DailyMed — Lithium carbonate · NLM MeSH — Lithium carbonate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Mood stabiliser; lithium salt used in bipolar disorder

Mechanism of action

The mechanism of mood stabilisation is not fully understood. Lithium modulates intracellular signalling pathways, including inhibition of glycogen synthase kinase-3 and effects on inositol-phosphate metabolism, and influences neuronal second-messenger systems.

General use cases

  • Treatment of acute manic episodes and maintenance treatment of bipolar I disorder in adults, with serum lithium concentration, renal, thyroid and electrolyte monitoring; indication and age criteria depend on the product label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Lithium Carbonate Environmental Risk Assessment (ERA) (the Lithium Carbonate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.